Janssen re­ports de­cline in 2022 net prices as out-of-pock­et costs grow

While net prices for Janssen’s com­mer­cial drugs have de­clined for the sixth con­sec­u­tive year, out-of-pock­et costs have con­tin­ued to rise for some pa­tients, ac­cord­ing to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER